AMCP 2024: Behind the research with YuQian Liu

Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier

April 17, 2024

As more high-priced cell and gene therapies come onto the market, the health care industry is faced with a fundamental challenge: to make sure that patients can access these life-saving treatments.

That was the focus of the day two session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting, “Future of Cell and Gene Therapy Management: There is More Than Value Based Contracting!”

We caught up with one of the presenters, YuQian Liu, senior director of specialty clinical solutions at Prime Therapeutics/Magellan Rx, to talk about how managed care pharmacy professionals can rise to this challenge.

Stay tuned for additional coverage from AMCP Annual 2024 on our newsroom, and follow us on LinkedIn or X (formerly Twitter).

Related news


May 20, 2024

Preventing opioid overdoses with naloxone

As prescription opioid overdoses rise in the U.S., the Prime/MRx Special Investigations Unit (SIU) shares how to identify if someone has overdosed and how you can help save a life


May 15, 2024

High-Cost Therapy Profile

Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV)


May 15, 2024

June 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market